Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2302032A (PRAME Immunotherapy) as Adjuvant Therapy in Resected NSCLC
NCT01853878Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2013
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes, Cancer Vaccines
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing GSK2302032A Group with Placebo Group (2 arms). Primary endpoint: Time to Occurrence of Any Recurrence of Disease. Started Jun 2013; status: completed.
02
Drugs
GSK2302032A
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01853878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853878.